Castle Biosciences, Inc. (CSTL) Earnings History
Annual and quarterly earnings data from 2017 to 2025
Loading earnings history...
CSTL EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CSTL Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 68.7% | -12.4% | -7.0% |
| 2024 | 81.9% | 2.6% | 5.5% |
| 2023 | 79.5% | -30.9% | -26.1% |
| 2022 | 76.6% | -53.2% | -49.0% |
| 2021 | 83.2% | -42.6% | -33.3% |
Download Data
Export CSTL earnings history in CSV or JSON format
Free sign-in required to download data
Castle Biosciences, Inc. (CSTL) Earnings Overview
As of May 8, 2026, Castle Biosciences, Inc. (CSTL) reported trailing twelve-month net income of -$13M, reflecting -233.9% year-over-year growth. The company earned $-0.43 per diluted share over the past four quarters, with a net profit margin of -7.0%.
Looking at the long-term picture, CSTL's historical earnings data spans multiple years. The company achieved its highest annual net income of $18M in fiscal 2024.
Castle Biosciences, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NTRA (-$208M net income, -9.0% margin), EXAS (-$208M net income, -6.4% margin), VCYT ($88M net income, 12.8% margin), CSTL has outperformed on profitability metrics. Compare CSTL vs NTRA →
CSTL Earnings vs Peers
Earnings metrics vs comparable public companies
CSTL Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$24M | -232.4% | -$43M | $-0.83 | -7.0% | -12.4% |
| 2024 | $18M | +131.7% | $9M | $0.62 | 5.5% | 2.6% |
| 2023 | -$57M | +14.4% | -$68M | $-2.14 | -26.1% | -30.9% |
| 2022 | -$67M | -114.6% | -$73M | $-2.58 | -49.0% | -53.2% |
| 2021 | -$31M | -204.3% | -$40M | $-1.24 | -33.3% | -42.6% |
| 2020 | -$10M | -294.9% | -$7M | $-0.54 | -16.4% | -10.4% |
| 2019 | $5M | +182.9% | $7M | $-0.21 | 10.2% | 14.1% |
| 2018 | -$6M | +48.5% | -$4M | $-0.60 | -27.9% | -16.8% |
| 2017 | -$12M | - | -$11M | $-1.26 | -89.9% | -79.2% |
See CSTL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CSTL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CSTL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCSTL — Frequently Asked Questions
Quick answers to the most common questions about buying CSTL stock.
Is CSTL growing earnings?
CSTL EPS fell to $-0.43, with earnings declining -233.9%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-13M.
What are CSTL's profit margins?
Castle Biosciences, Inc. net margin is -7.0%, with operating margin at -12.4%. Below-average margins reflect competitive or cost pressures.
How consistent are CSTL's earnings?
CSTL earnings data spans 2017-2025. The declining earnings trend is -233.9% YoY. Historical data enables comparison across business cycles.